These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
224 related articles for article (PubMed ID: 20655261)
1. Safety and immunogenicity of an investigational quadrivalent meningococcal CRM(197) conjugate vaccine, MenACWY-CRM, compared with licensed vaccines in adults in Latin America. Stamboulian D; Lopardo G; Lopez P; Cortes-Barbosa C; Valencia A; Bedell L; Karsten A; Dull PM Int J Infect Dis; 2010 Oct; 14(10):e868-75. PubMed ID: 20655261 [TBL] [Abstract][Full Text] [Related]
2. Phase III comparison of an investigational quadrivalent meningococcal conjugate vaccine with the licensed meningococcal ACWY conjugate vaccine in adolescents. Jackson LA; Baxter R; Reisinger K; Karsten A; Shah J; Bedell L; Dull PM; Clin Infect Dis; 2009 Jul; 49(1):e1-10. PubMed ID: 19476428 [TBL] [Abstract][Full Text] [Related]
3. A randomized trial to determine the tolerability and immunogenicity of a quadrivalent meningococcal glycoconjugate vaccine in healthy adolescents. Jackson LA; Jacobson RM; Reisinger KS; Anemona A; Danzig LE; Dull PM Pediatr Infect Dis J; 2009 Feb; 28(2):86-91. PubMed ID: 19116603 [TBL] [Abstract][Full Text] [Related]
4. Immunogenicity and immune memory of a nonadjuvanted quadrivalent meningococcal glycoconjugate vaccine in infants. Perrett KP; Snape MD; Ford KJ; John TM; Yu LM; Langley JM; McNeil S; Dull PM; Ceddia F; Anemona A; Halperin SA; Dobson S; Pollard AJ Pediatr Infect Dis J; 2009 Mar; 28(3):186-93. PubMed ID: 19209097 [TBL] [Abstract][Full Text] [Related]
5. Quadrivalent meningococcal vaccination of adults: phase III comparison of an investigational conjugate vaccine, MenACWY-CRM, with the licensed vaccine, Menactra. Reisinger KS; Baxter R; Block SL; Shah J; Bedell L; Dull PM Clin Vaccine Immunol; 2009 Dec; 16(12):1810-5. PubMed ID: 19812260 [TBL] [Abstract][Full Text] [Related]
6. Immunogenicity and safety of the 4CMenB and MenACWY-CRM meningococcal vaccines administered concomitantly in infants: A phase 3b, randomized controlled trial. Macias Parra M; Gentile A; Vazquez Narvaez JA; Capdevila A; Minguez A; Carrascal M; Willemsen A; Bhusal C; Toneatto D Vaccine; 2018 Nov; 36(50):7609-7617. PubMed ID: 30414782 [TBL] [Abstract][Full Text] [Related]
7. Immunogenicity and tolerability of a quadrivalent meningococcal glycoconjugate vaccine in children 2-10 years of age. Black S; Klein NP; Shah J; Bedell L; Karsten A; Dull PM Vaccine; 2010 Jan; 28(3):657-63. PubMed ID: 19895922 [TBL] [Abstract][Full Text] [Related]
8. Safety and immunogenicity of a novel quadrivalent meningococcal CRM-conjugate vaccine given concomitantly with routine vaccinations in infants. Klein NP; Reisinger KS; Johnston W; Odrljin T; Gill CJ; Bedell L; Dull P Pediatr Infect Dis J; 2012 Jan; 31(1):64-71. PubMed ID: 22094635 [TBL] [Abstract][Full Text] [Related]
9. Safety and immunogenicity of typhoid fever and yellow fever vaccines when administered concomitantly with quadrivalent meningococcal ACWY glycoconjugate vaccine in healthy adults. Alberer M; Burchard G; Jelinek T; Reisinger E; Beran J; Hlavata LC; Forleo-Neto E; Dagnew AF; Arora AK J Travel Med; 2015; 22(1):48-56. PubMed ID: 25308927 [TBL] [Abstract][Full Text] [Related]
10. Immunogenicity and safety of concomitant administration of a combined hepatitis A/B vaccine and a quadrivalent meningococcal conjugate vaccine in healthy adults. Alberer M; Burchard G; Jelinek T; Reisinger EC; Meyer S; Forleo-Neto E; Dagnew AF; Arora AK J Travel Med; 2015; 22(2):105-14. PubMed ID: 25483566 [TBL] [Abstract][Full Text] [Related]
11. Immunogenicity and safety of a novel quadrivalent meningococcal conjugate vaccine (MenACWY-CRM) in healthy Korean adolescents and adults. Lee HJ; Chung MH; Kim WJ; Hong YJ; Choi KM; Lee J; Oh CE; Welsch JA; Kim KH; Hong KB; Dagnew AF; Bock H; Dull PM; Odrljin T Int J Infect Dis; 2014 Nov; 28():204-10. PubMed ID: 25316331 [TBL] [Abstract][Full Text] [Related]
12. Antibody persistence after primary and booster doses of a quadrivalent meningococcal conjugate vaccine in adolescents. Baxter R; Reisinger K; Block SL; Percell S; Odrljin T; Dull PM; Smolenov I Pediatr Infect Dis J; 2014 Nov; 33(11):1169-76. PubMed ID: 24911896 [TBL] [Abstract][Full Text] [Related]
13. Safety of a quadrivalent meningococcal serogroups A, C, W and Y conjugate vaccine (MenACWY-CRM) administered with routine infant vaccinations: results of an open-label, randomized, phase 3b controlled study in healthy infants. Abdelnour A; Silas PE; Lamas MR; Aragón CF; Chiu NC; Chiu CH; Acuña TH; Castrejón Tde L; Izu A; Odrljin T; Smolenov I; Hohenboken M; Dull PM Vaccine; 2014 Feb; 32(8):965-72. PubMed ID: 24397906 [TBL] [Abstract][Full Text] [Related]
14. Antibody persistence and booster response of a quadrivalent meningococcal conjugate vaccine in adolescents. Baxter R; Reisinger K; Block SL; Izu A; Odrljin T; Dull P J Pediatr; 2014 Jun; 164(6):1409-15.e4. PubMed ID: 24657122 [TBL] [Abstract][Full Text] [Related]
15. Comparison of the safety and immunogenicity of an investigational and a licensed quadrivalent meningococcal conjugate vaccine in children 2-10 years of age. Halperin SA; Gupta A; Jeanfreau R; Klein NP; Reisinger K; Walter E; Bedell L; Gill C; Dull PM Vaccine; 2010 Nov; 28(50):7865-72. PubMed ID: 20943209 [TBL] [Abstract][Full Text] [Related]
16. Antibody persistence and response to a booster dose of a quadrivalent conjugate vaccine for meningococcal disease in adolescents. Jacobson RM; Jackson LA; Reisinger K; Izu A; Odrljin T; Dull PM Pediatr Infect Dis J; 2013 Apr; 32(4):e170-7. PubMed ID: 23114372 [TBL] [Abstract][Full Text] [Related]
17. Immunogenicity and safety of a quadrivalent meningococcal conjugate vaccine administered concomitantly with measles, mumps, rubella, varicella vaccine in healthy toddlers. Klein NP; Shepard J; Bedell L; Odrljin T; Dull P Vaccine; 2012 Jun; 30(26):3929-36. PubMed ID: 22504039 [TBL] [Abstract][Full Text] [Related]
18. Safety and immunogenicity of one dose of MenACWY-CRM, an investigational quadrivalent meningococcal glycoconjugate vaccine, when administered to adolescents concomitantly or sequentially with Tdap and HPV vaccines. Arguedas A; Soley C; Loaiza C; Rincon G; Guevara S; Perez A; Porras W; Alvarado O; Aguilar L; Abdelnour A; Grunwald U; Bedell L; Anemona A; Dull PM Vaccine; 2010 Apr; 28(18):3171-9. PubMed ID: 20189491 [TBL] [Abstract][Full Text] [Related]
19. A comparative evaluation of two investigational meningococcal ABCWY vaccine formulations: Results of a phase 2 randomized, controlled trial. Block SL; Szenborn L; Daly W; Jackowska T; D'Agostino D; Han L; Dull PM; Smolenov I Vaccine; 2015 May; 33(21):2500-10. PubMed ID: 25795256 [TBL] [Abstract][Full Text] [Related]
20. Safety and immunogenicity of a booster dose of meningococcal (groups A, C, W, and Y) polysaccharide diphtheria toxoid conjugate vaccine. Robertson CA; Greenberg DP; Hedrick J; Pichichero M; Decker MD; Saunders M Vaccine; 2016 Oct; 34(44):5273-5278. PubMed ID: 27642132 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]